fashion -WSS

fashion

author：knowledge 2025-09-27 10:01:15 - browse：2

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： VC firm General Catalyst wants to buy a health system

focus

explore

focus

WSS

Liquid biopsy for lung cancer is launched by Delfi

My daughter's legacy lives on through her writing, phage therapy

VC firm General Catalyst wants to buy a health system

Cigna wins case to block Amy Bricker's move to CVS

Readers discuss the intersection of pregnancy and addiction

New report analyzes digital physical therapy solutions' effectiveness

Wikipedia

fashion

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Bristol 'take

Hollywood unions extend contract negotiations for actors

Sana to lay off nearly a third of staff, de

Continuity nursing helped my family in our darkest PICU moments

Curing rare childhood diseases will falter unless Congress steps up

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Deposition: Sackler embraced plan to conceal OxyContin’s strength

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Analysis of telehealth claims data suggest service duplication

focus

Cheap, fast test for Zika and dengue could cost just $1

Stroke deaths set to near 10 million globally by 2050

AI can decode, harness the power of the humane immune system

FDA authorizes Novavax’s updated Covid

Pharma companies must ensure equitable access to obesity drugs

Teladoc has a new CEO, but challenges remain the same

focus

explore

focus

entertainment